Beijing, China, July 12, 2023-- In the first quarter of this year, the Brazilian Ministry of Health announced a shortage of insulin supply, stating that millions of rapid-acting insulin products were urgently needed. This news caused great concern within the Brazilian community and the pharmaceutical industry. Recognizing the potential medication risk to Brazilian patients, Gan & Lee Pharmaceuticals (stock code: 603087. SH) took proactive measures and initiated multiple rounds of communication with the relevant Brazilian authorities to fully understand the actual demand. After a meticulous bidding process and official product technical evaluation, Gan & Lee won the tender for the insulin aspart injections and reusable insulin pen products developed by the company. The first batch of these products has already been successfully shipped, marking the completion of the first set of deliveries. 

The shipment includes 1.34 million cartridges of 3 mL insulin aspart injections and 67,000 reusable insulin pens. To ensure convenience and ease of use for local patients, the products were well packaged in Portuguese in strict compliance with local regulations. Gan & Lee has already gained valuable experience serving the Brazilian market through the successful registration and commercialization of the insulin glargine product. The company's advantage lies in its own production capacity, supported by a well-developed and comprehensive supply chain system. In addition, Gan & Lee's exceptional attention and unwavering support during this drug shortage event played a critical role in achieving the delivery in an impressively short timeframe.

Gan & Lee has consistently prioritized the well-being of patients throughout the Brazilian insulin bidding process. With an unwavering commitment to quality and quantity assurance, the company expedited the arrival of these medicines in Brazil. This expedited delivery aims to ensure patients receive timely treatment, thereby safeguarding their lives and overall health. Moving forward, Gan & Lee remains steadfast in fulfilling its mission and social responsibility. The company will continue to provide high-quality products and services to patients worldwide and actively contribute to advancing human health and well-being.

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.